Synergy Pharmaceuticals, Inc. (SGYP) SEC Filing 10-Q Quarterly report for the period ending Saturday, March 31, 2018

Exhibit 99.1

Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update

·                  TRULANCE only CIC/IBS-C Rx brand to grow in total and new Rx volume quarter-over-quarter, per IQVIA

·                  Synergy lowers 2018 adjusted operating expense (non-GAAP) guidance

·                                          Initiated strategic partnership with the National Cancer Institute (NCI) to collaborate on study to evaluate dolcanatide’s potential to prevent colorectal cancer

·                                          Conducting ongoing review of strategic business development options focused on maximizing shareholder value

NEW YORK, May 10, 2018 —Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March 31, 2018.

“The first quarter of 2018 was all about executing on our three key business priorities of optimizing the value of TRULANCE, ensuring a strong financial foundation, and continuing to explore all strategic business development opportunities,” said Troy Hamilton, Chief Executive Officer of Synergy Pharmaceuticals Inc.  “With TRULANCE, we saw continued growth in prescriptions, market share and its prescriber base and with the IBS-C launch in late February, we have the opportunity to continue to drive further sales growth. In addition, we continued to efficiently manage our operating expenses by prioritizing key investments in areas of high return, such as expanding market access.  Finally, we amended our debt agreement to allow for more flexible access to capital as we are pursuing strategic options that align with our core mission to deliver exceptional value to our patients, customers and shareholders. Overall, our progress against our key business priorities during the first quarter reflect our commitment to maximizing shareholder value while also maintaining our focus on providing safe and effective treatment options for patients living with chronic GI conditions.”

First Quarter 2018 and Recent Highlights

Optimizing the Value of TRULANCE

·                  44,177 TRULANCE 30-count packs were dispensed in the first quarter of 2018, resulting in a total of 132,628 TRULANCE 30-count packs dispensed since the product’s launch on March 20, 2017, per IQVIA.

·                  TRULANCE was the only prescription brand for CIC and IBS-C to show positive total and new prescription volume growth in the first quarter over the prior quarter, per IQVIA.

·                  In the nine weeks since the launch of the IBS-C indication in late February, TRULANCE prescription volume grew 24% versus the prior nine weeks or nearly five times the branded CIC and IBS-C prescription market growth rate, per IQVIA.

·                  The total number of unique healthcare practitioners prescribing TRULANCE since launch reached nearly 12,000 in the first quarter of 2018, increasing more than 20% over the prior quarter, per IQVIA.

·                  TRULANCE currently has over 70% payer coverage across all segments including commercial, Medicare Part D and Managed Medicaid.

Ensuring a Strong Financial Foundation

Financial Results